Patents by Inventor Martin Donovan

Martin Donovan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220295761
    Abstract: Systems and methods for cultivating or accumulating climate-focused marine target products are described herein. The target product may be microalgae, macroalgae, plankton, marine bacteria or archaea, filter feeders (such as oysters or clams), or crustaceans either for the purpose of bioremediation, eventual cultivation or for sequestering carbon dioxide; or the target product may be direct chemical or biological accumulation of carbon or carbon containing organisms. The system is primarily a floating apparatus designed to hold the target product in a region of the water column and in a spatial region of the water where it will best accumulate target product mass. In some embodiments the system is designed to achieve eventual passive sinking (transformation from a floating to sinking apparatus) into the deep ocean. In some embodiments, the system is equipped with purpose-chosen sensors to instrument and quantify the various biological and mechanical processes occurring onboard.
    Type: Application
    Filed: June 7, 2022
    Publication date: September 22, 2022
    Applicant: Running Tide Technologies, Inc.
    Inventors: Nathaniel MERRILL, Max CHALFIN, Andrew Clyde THOMPSON, Margaux MARTIN-FILIPPI, Finnian Cradock DONOVAN, Matthew Jordan ODLIN
  • Patent number: 11382315
    Abstract: Systems and methods for cultivating or accumulating climate-focused marine target products are described herein. The target product may be microalgae, macroalgae, plankton, marine bacteria or archaea, filter feeders (such as oysters or clams), or crustaceans either for the purpose of bioremediation, eventual cultivation or for sequestering carbon dioxide; or the target product may be direct chemical or biological accumulation of carbon or carbon containing organisms. The system is primarily a floating apparatus designed to hold the target product in a region of the water column and in a spatial region of the water where it will best accumulate target product mass. In some embodiments the system is designed to achieve eventual passive sinking (transformation from a floating to sinking apparatus) into the deep ocean. In some embodiments, the system is equipped with purpose-chosen sensors to instrument and quantify the various biological and mechanical processes occurring onboard.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: July 12, 2022
    Assignee: Running Tide Technologies, Inc.
    Inventors: Nathaniel Merrill, Max Chalfin, Andrew Clyde Thompson, Margaux Martin-Filippi, Finnian Cradock Donovan, Matthew Jordan Odlin
  • Publication number: 20220079949
    Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.
    Type: Application
    Filed: November 23, 2021
    Publication date: March 17, 2022
    Applicant: Respira Therapeutics, Inc.
    Inventors: Jeffry Weers, Alain Romero, Hugh Smyth, Robert Curtis, Adaani Frost, Zhen Xu, Revati Shreeniwas, Martin Donovan
  • Patent number: 11129940
    Abstract: This disclosure includes syringes, kits containing the same, and related methods. Some syringes are pre-loaded with paste and have a syringe body defining a reservoir having an internal first transverse dimension, a paste disposed within the reservoir, the paste having a solids concentration of greater than 50 mg/mL, a needle defining a lumen having an internal second transverse dimension that is smaller than the first transverse dimension, the needle configured to be in fluid communication with the reservoir to allow intracutaneous delivery of the paste, and a plunger and/or piston disposed within the reservoir and configured to be moved to dispense paste from the reservoir through the lumen. Some syringes include a fitting (e.g. Luer fitting) disposed on the syringe body and in fluid communication with the reservoir and a sealing cap disposed on the Luer fitting to seal the reservoir.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: September 28, 2021
    Assignee: Xeris Pharmaceuticals, Inc.
    Inventor: Martin Donovan
  • Publication number: 20210205318
    Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.
    Type: Application
    Filed: January 11, 2021
    Publication date: July 8, 2021
    Inventors: Jeffry WEERS, Alain ROMERO, Hugh SMYTH, Robert CURTIS, Adaani FROST, Zhen XU, Revati SHREENIWAS, Martin DONOVAN
  • Patent number: 10912778
    Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: February 9, 2021
    Assignee: RESPIRA THERAPEUTICS, INC.
    Inventors: Jeffry Weers, Alain Romero, Hugh Smyth, Robert Curtis, Adaani Frost, Zhen Xu, Revati Shreeniwas, Martin Donovan
  • Publication number: 20200376083
    Abstract: The present invention concerns the use of aprotic polar solvents, water, and an ionization stabilizing agent to prepare device compatible stable therapeutic formulations by dissolving a therapeutic agent (active ingredient) in an aprotic polar solvent system that can then be used with various devices (e.g., pumps, infusion sets) for administration of the formulation. In certain embodiments, the invention is directed to formulations comprising one or more therapeutic agents, as well as methods of making such formulations, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system, such as a DMSO/water admixture, comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.
    Type: Application
    Filed: May 29, 2020
    Publication date: December 3, 2020
    Applicant: XERIS PHARMACEUTICALS, INC.
    Inventors: Martin DONOVAN, Wendy HU
  • Publication number: 20200215162
    Abstract: Certain embodiments are directed to a formulation of a therapeutic agent, as well as a method of making such a formulation, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.
    Type: Application
    Filed: October 14, 2019
    Publication date: July 9, 2020
    Inventors: Steven Prestrelski, Michael Sandoval, Martin Donovan
  • Publication number: 20200179624
    Abstract: A dry powder inhaler includes a powder storage element configured to hold a powdered medicament and an inlet channel receives powdered medicament from the powder storage element that is entrained in an airflow. The inlet channel has a first diameter and defines an opening. The inhaler includes a dispersion chamber that receives the airflow and the powdered medicament from the opening. The dispersion chamber has a second diameter. The inhaler includes an actuator housed within the dispersion chamber. The actuator oscillates within the dispersion chamber when exposed to the airflow to deaggregate the powdered medicament entrained by the airflow passing through the dispersion chamber. A ratio between the first diameter and the second diameter is between about 0.40 and 0.60 such that an audible sound is produced as the actuator oscillates. The inhaler includes an outlet channel through which the airflow and powdered medicament exit the inhaler.
    Type: Application
    Filed: November 18, 2019
    Publication date: June 11, 2020
    Inventors: Robert M. Curtis, Dan Deaton, James Hannon, Hugh Smyth, Zhen Xu, Martin Donovan, Aileen Gibbons
  • Publication number: 20200093830
    Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.
    Type: Application
    Filed: December 14, 2017
    Publication date: March 26, 2020
    Inventors: Jeffry WEERS, Alain ROMERO, Hugh SMYTH, Robert CURTIS, Adaani FROST, Zhen XU, Revati SHREENIWAS, Martin DONOVAN
  • Patent number: 10525216
    Abstract: A dry powder inhaler includes a powder storage element configured to hold a powdered medicament and an inlet channel receives powdered medicament from the powder storage element that is entrained in an airflow. The inlet channel has a first diameter and defines an opening. The inhaler includes a dispersion chamber that receives the airflow and the powdered medicament from the opening. The dispersion chamber has a second diameter. The inhaler includes an actuator housed within the dispersion chamber. The actuator oscillates within the dispersion chamber when exposed to the airflow to deaggregate the powdered medicament entrained by the airflow passing through the dispersion chamber. A ratio between the first diameter and the second diameter is between about 0.40 and 0.60 such that an audible sound is produced as the actuator oscillates. The inhaler includes an outlet channel through which the airflow and powdered medicament exit the inhaler.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: January 7, 2020
    Assignee: Respira Therapeutics, Inc.
    Inventors: Robert M. Curtis, Dan Deaton, James Hannon, Hugh Smyth, Zhen Xu, Martin Donovan, Aileen Gibbons
  • Patent number: 10485850
    Abstract: Certain embodiments are directed to a formulation of a therapeutic agent, as well as a method of making such a formulation, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: November 26, 2019
    Assignee: XERIS PHARMACEUTICALS, INC.
    Inventors: Steven Prestrelski, Michael Sandoval, Martin Donovan
  • Publication number: 20190224428
    Abstract: A dry powder inhaler includes a powder storage element configured to hold a powdered medicament and an inlet channel receives powdered medicament from the powder storage element that is entrained in an airflow. The inlet channel has a first diameter and defines an opening. The inhaler includes a dispersion chamber that receives the airflow and the powdered medicament from the opening. The dispersion chamber has a second diameter. The inhaler includes an actuator housed within the dispersion chamber. The actuator oscillates within the dispersion chamber when exposed to the airflow to deaggregate the powdered medicament entrained by the airflow passing through the dispersion chamber. A ratio between the first diameter and the second diameter is between about 0.40 and 0.60 such that an audible sound is produced as the actuator oscillates. The inhaler includes an outlet channel through which the airflow and powdered medicament exit the inhaler.
    Type: Application
    Filed: January 14, 2016
    Publication date: July 25, 2019
    Applicant: Respira Therapeutics, Inc.
    Inventors: Robert M. Curtis, Dan Deaton, James Hannon, Hugh Smyth, Zhen Xu, Martin Donovan, Aileen Gibbons
  • Publication number: 20190083578
    Abstract: The present invention provides methods for controlling or reducing caloric intake in a subject by administering a low dose of a stable glucagon formulation. The present invention further provides methods for treating mild or moderate hypoglycemia in a subject in need thereof subject by administering a low dose of a stable glucagon formulation. Kits for practicing the methods of the invention are also provided.
    Type: Application
    Filed: June 10, 2016
    Publication date: March 21, 2019
    Inventors: Yashvinder SABHARWAL, Steven PRESTRELSKI, Michael SANDOVAL, Martin DONOVAN
  • Publication number: 20180271948
    Abstract: Certain embodiments are directed to a formulation of a therapeutic agent, as well as a method of making such a formulation, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.
    Type: Application
    Filed: September 25, 2016
    Publication date: September 27, 2018
    Inventors: Steven PRESTRELSKI, Martin DONOVAN, Michael SANDOVAL
  • Publication number: 20170312341
    Abstract: Certain embodiments are directed to a formulation of a therapeutic agent, as well as a method of making such a formulation, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.
    Type: Application
    Filed: May 15, 2017
    Publication date: November 2, 2017
    Inventors: Steven Prestrelski, Michael Sandoval, Martin Donovan
  • Publication number: 20170216529
    Abstract: This disclosure includes syringes, kits containing the same, and related methods. Some syringes are pre-loaded with paste and have a syringe body defining a reservoir having an internal first transverse dimension, a paste disposed within the reservoir, the paste having a solids concentration of greater than 50 mg/mL, a needle defining a lumen having an internal second transverse dimension that is smaller than the first transverse dimension, the needle configured to be in fluid communication with the reservoir to allow intracutaneous delivery of the paste, and a plunger and/or piston disposed within the reservoir and configured to be moved to dispense paste from the reservoir through the lumen. Some syringes include a fitting (e.g. Luer fitting) disposed on the syringe body and in fluid communication with the reservoir and a sealing cap disposed on the Luer fitting to seal the reservoir.
    Type: Application
    Filed: August 6, 2015
    Publication date: August 3, 2017
    Inventor: Martin DONOVAN
  • Patent number: 9649364
    Abstract: Certain embodiments are directed to a formulation of a therapeutic agent, as well as a method of making such a formulation, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: May 16, 2017
    Assignee: XERIS PHARMACEUTICALS, INC.
    Inventors: Steven Prestrelski, Michael Sandoval, Martin Donovan
  • Publication number: 20170087215
    Abstract: Certain embodiments are directed to a formulation of a therapeutic agent, as well as a method of making such a formulation, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.
    Type: Application
    Filed: April 22, 2016
    Publication date: March 30, 2017
    Inventors: Steven Prestrelski, Michael Sandoval, Martin Donovan
  • Publication number: 20170007675
    Abstract: Disclosed is a stable formulation for parenteral injection, as well as methods for its use and preparation, that includes a peptide or a salt thereof that has been previously dried from an aqueous composition comprising a partially volatile buffer, a volatile buffer, a strong acid, or a strong base, or any combination thereof, wherein the dried peptide or salt thereof has a first ionization profile that corresponds to the peptide's optimal stability and solubility, and an aprotic polar solvent, wherein the dried peptide or salt thereof is reconstituted into an aprotic polar solvent and has a second ionization profile in the aprotic polar solvent, wherein the first and second ionization profiles are substantially the same, such as within 1 pH unit of one another.
    Type: Application
    Filed: February 6, 2015
    Publication date: January 12, 2017
    Inventors: Steven PRESTRELSKI, Martin DONOVAN